North America
As the patents for current biologics expire and the biosimilar industry begins to gain traction it is important to look at the future of the biosimilar market while noting hold-backs within the US manufacturing and approval processes. According to Research and...
Europe
Over the last two decades, biologics have revolutionized the treatment of illnesses such as diabetes, cancer, rheumatoid arthritis and hepatitis. However, many prominent biologics are about to have their patents expire in the U.S., making way for biosimilars....
#WednesdayWebinar Join us for our upcoming webinar Global Regulatory Changes to Expect in 2025 January 22, 2025 at 10 AM ET
Register Now
